Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31707398 | 1.00 | UCHL1 (0.40) | UCHL1ALDH1A1POLBKDM4EHPGD | |
| SCHEMBL1358786 | 0.80 | UCHL1 (0.41) | UCHL1FFAR1 | |
| SCHEMBL24896720 | 0.79 | UCHL1 (0.44) | UCHL1FFAR1 | |
| SCHEMBL31707399 | 0.79 | ALDH1A1 (0.35) | ALDH1A1POLBKDM4EFFAR1 | |
| SCHEMBL31030395 | 0.78 | FFAR1 (0.49) | ALDH1A1POLBKDM4EHPGDFFAR1 | |
| SCHEMBL24896603 | 0.77 | UCHL1 (0.42) | UCHL1FFAR1 | |
| SCHEMBL21266730 | 0.76 | UCHL1 (0.38) | UCHL1FFAR1 | |
| SCHEMBL25428252 | 0.75 | UCHL1 (0.43) | UCHL1FFAR1 | |
| SCHEMBL30201150 | 0.75 | UCHL1 (0.41) | UCHL1FFAR1 | |
| SCHEMBL30200828 | 0.72 | UCHL1 (0.42) | UCHL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | UCHL1 2802/4885ALDH1A1 741/4885POLB 2231/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | UCHL1 3897/4885ALDH1A1 1830/4885POLB 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.